LINC Linc AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million ($2.99 million) and SEK 250 million ($29.99 million), the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB was founded in 1991 and based in Stockholm, Sweden.…
Industry Peers
Asset ManagementKey Statistics
About Linc (STO: LINC)
›
Linc (STO: LINC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Asset Management industry, part of the Financial Services sector, and reports about 2 employees.
The shares were at 75.00 SEK on 19 November 2026, up 6.7% over 52 weeks. Its 52-week range is 58.90 SEK to 78.10 SEK: the price is 4.0% below the high and 27.3% above the low.
At a market capitalisation of 4.31B SEK, it trades at 62.5 times trailing earnings. The median trailing P/E of its 18 largest Asset Management peers is 15.2, a premium of 312% for LINC.
Linc reports return on equity of -9.0%, an operating margin of 86.9% and revenue down 68.7% year over year.
It holds more cash than debt, a net cash position of 65.59M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 75.00 SEK is 0.0% above the current price.